MOSCOW (Reuters) – Russia’s Sputnik V vaccine has demonstrated 96.3% efficacy against COVID-19 during the vaccination campaign in Belarus, Russia’s RDIF sovereign wealth fund said on Wednesday, down from 97.2% efficacy reported in September.
The Russian Direct Investment Fund, which is marketing the two-shot vaccine abroad, said the study was based on data from more than 1.2 million people who had been vaccinated with both Sputnik V components between January and September 2021.
(Reporting by Maria Kiselyova; Writing by Alexander Marrow)